Clinical Trial Update: Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating cytokine-armored GPC3-targeted CAR-T cells in adults with solid tumors, including hepatocellular carcinoma; the study is currently not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Liposarcoma
• Rhabdomyosarcoma
• Yolk Sac Tumor

Drugs mentioned

• Cytokine Armored GPC3 CAR-T

Snippet

Sponsor: Seattle Children's Hospital | Conditions: Solid Tumor (Excluding CNS), Hepatocellular Carcinoma | Phase 1 | Status: NOT_YET_RECRUITING